

Damtix 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg

Authorised

- Imidacloprid
- Permethrin (40:60)

Product identification

Medicine name:

Damtix 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg

Active substance:

Imidacloprid

Permethrin (40:60)

Target species:

Dog

Route of administration:

Spot-on use

Product details

Active substance and strength:

Imidacloprid

100.00 milligram(s) / 1.00 Pipette

Permethrin (40:60)
500.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP53AC54

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Greece

Available in:

Greece

Package description:

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 1 pipette

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 3 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 4 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 6 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 10 pipettes

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

21/06/2022

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

National Organization For Medicines

Authorisation number:

67542/22-06-2022/K-0248902

Date of authorisation status change:

21/06/2022

Reference member state:

Ireland

Procedure number:

IE/V/0663/002

Concerned member states:

Finland France Germany Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents